Trial | NCT00739440  Report issue

Title

Randomized Controlled Trial to Compare Two Anti-scorpion Serums
Randomized Controlled Trial to Evaluate Efficiency and Safety of the Polyvalent Antiscorpion Serum of Birmex Versus Other Commercial Serum

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    120
The purpose of this study is to compare the efficiency and safety of the treatment against sting scorpion, using two serums, one elaborated by Birmex versus other commercial serum
We consider relevant conduct this study because the poisoning scorpion bite represents a public health problem.

This is a randomized clinical trial, which included 120 subjects of both sexes aged 15 and 60 years old and residents of the state of Guanajuato, divided into 2 groups: 60 patients received antiscorpion serum of Birmex and 60 patients receive other commercial serum.
Study Started
Aug 31
2008
Primary Completion
Oct 31
2008
Study Completion
Nov 30
2008
Last Update
Aug 07
2013
Estimate

Biological serum antiscorpion

The dose may be required for the patient according to clinical manifestations and evolution

  • Other names: anti-Scorpion venom Serum

I Experimental

Patients 15 to 60 years with scorpion sting, will receive serum antiscorpion elaborated by Birmex

II Experimental

Patients 15 to 60 years with scorpion sting, will receive other commercial serum antiscorpion (Alacramyn)

Criteria 

Inclusion Criteria:

Sting scorpion
Informed consent
Age 15-60
Either sex
Resident in study area

Exclusion Criteria:

Previous treatment with gammaglobulin
Blood transfusion at any stage of life
Sensitivity or intolerance to serums antiscorpion or horse products
Pregnancy
Some immunodeficiency
No Results Posted